CCR4 and familial pancreatic carcinoma: Based on our results, we suggest that antagonizing CCR4 could be beneficial as an adjuvant strategy in pancreatic cancer therapy to mitigate the immunomodulatory potential of the remaining cancer cells after curative surgery and prolong the relapse-free period.